The advertisement promotes CABOMETYX (cabozantinib) tablets for treating certain types of pancreatic neuroendocrine tumors in patients aged 12 and older. It includes a call to action to learn more and provides important safety information regarding potential serious side effects.
Creative Information
| CID: | f537253b-5708-456c-8ae5-39924a5c7681 |
| CRID: | 82_6157-850395 |
| Domain: | exelixis.com |
| Seat: | PP |
| Size: | 300x250 |
| Bid: | $0.87 |
| Timestamp: | 10/31/2025, 1:25:19 AM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 10/31/2025, 2:19:20 AM | 5.71s | |
| adomain_analysis | success | 10/31/2025, 4:32:53 AM | 3.18s | |
| adomain_capture | success | 10/31/2025, 4:32:50 AM | 0.11s | |
| ad_render | success | 10/31/2025, 2:19:14 AM | 24.88s | |
| brand_mapping | success | 10/31/2025, 1:25:20 AM | 0.68s | |
Analysis Results
Ad Format: banner
Brands: Exelixis
Sensitive:Misleading Health ClaimsUnverified Medical TreatmentsPharmaceutical Products
Quality:Adomain not match landing page domain
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1858.32 KB | ||||||||||||||||||||||
| Render Time: | 9.43 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1858.44 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives
